SEC Investigating Cassava Sciences, Developer of Experimental Alzheimer's Drug

Cassava Sciences, one of best-performing U.S. stocks this year, has denied claims that it manipulated research results.

This site uses cookies to help personalise content, tailor your experience and to keep you logged in if you register.
By continuing to use this site, you are consenting to our use of cookies.
Accept Learn more…